The effect on the small bowel of 5-FU and oxaliplatin in combination with radiation using a microcolony survival assay

Radiation Oncology

Volumn 4, Issue 1, 2009, Pages

  Gunnlaugsson, Adalsteinn ^a   Nilsson, Per ^a,b   Kjellén, Elisabeth ^a,b   Johnsson, Anders ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b UMEÅ UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; OXALIPLATIN; ANTINEOPLASTIC AGENT; PLATINUM COMPLEX;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE INCREASE; INTESTINE CRYPT; INTESTINE INJURY; MOUSE; NONHUMAN; PHOTON THERAPY; RADIATION DOSE; RADIATION RESPONSE; SINGLE DRUG DOSE; WHOLE BODY RADIATION; ANIMAL; BAGG ALBINO MOUSE; DRUG EFFECT; INTESTINE MUCOSA; MULTIMODALITY CANCER THERAPY; RADIATION EXPOSURE; SMALL INTESTINE;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; FLUOROURACIL; INTESTINAL MUCOSA; INTESTINE, SMALL; MICE; MICE, INBRED BALB C; ORGANOPLATINUM COMPOUNDS; RADIOTHERAPY DOSAGE; WHOLE-BODY IRRADIATION;

EID: 73249132436     PISSN: None     EISSN: 1748717X     Source Type: Journal    
DOI: 10.1186/1748-717X-4-61     Document Type: Article

References (26)

1. Gerard J-P, Conroy T, Bonnetain F, Bouche O, Chapet O, Closon-Dejardin M-T, Untereiner M, Leduc B, Francois E, Maurel J, Seitz JF, Buecher B, Mackiewicz R, Ducreux M, Bedenne L. Preoperative Radiotherapy With or Without Concurrent Fluorouracil and Leucovorin in T3-4 Rectal Cancers: Results of FFCD 9203. J Clin Oncol 2006, 24:4620-4625. 10.1200/JCO.2006.06.7629, 17008704.
2. Bosset J-F, Collette L, Calais G, Mineur L, Maingon P, Radosevic-Jelic L, Daban A, Bardet E, Beny A, Ollier J-C, Trial ERG. Chemotherapy with Preoperative Radiotherapy in Rectal Cancer. N Engl J Med 2006, 355:1114-1123. 10.1056/NEJMoa060829, 16971718.
3. Braendengen M, Tveit KM, Berglund A, Birkemeyer E, Frykholm G, Pahlman L, Wiig JN, Bystrom P, Bujko K, Glimelius B. Randomized Phase III Study Comparing Preoperative Radiotherapy With Chemoradiation in Nonresectable Rectal Cancer. J Clin Oncol 2008, 26:3687-3694. 10.1200/JCO.2007.15.3858, 18669453.
4. Andre T, Boni C, Mounedji-Boudiaf L, Navarro M, Tabernero J, Hickish T, Topham C, Zaninelli M, Clingan P, Bridgewater J, Tabah-Fisch I, de Gramont A, . Multicenter International Study of Oxaliplatin/5-Fluorouracil/Leucovorin in the Adjuvant Treatment of Colon Cancer (MOSAIC) Investigators Oxaliplatin, Fluorouracil, and Leucovorin as Adjuvant Treatment for Colon Cancer. N Engl J Med 2004, 350:2343-2351. 10.1056/NEJMoa032709, 15175436.
5. Giacchetti S, Perpoint B, Zidani R, Le Bail N, Faggiuolo R, Focan C, Chollet P, Llory JF, Letourneau Y, Coudert B, Bertheaut-Cvitkovic F, Larregain-Fournier D, Le Rol A, Walter S, Adam R, Misset JL, Lévi F. Phase III Multicenter Randomized Trial of Oxaliplatin Added to Chronomodulated Fluorouracil-Leucovorin as First-Line Treatment of Metastatic Colorectal Cancer. J Clin Oncol 2000, 18:136-47.
6. de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, Boni C, Cortes-Funes H, Cervantes A, Freyer G, Papamichael D, Le Bail N, Louvet C, Hendler D, de Braud F, Wilson C, Morvan F, Bonetti A. Leucovorin and Fluorouracil With or Without Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer. J Clin Oncol 2000, 18:2938-2947.
7. Chau I, Brown G, Cunningham D, Tait D, Wotherspoon A, Norman AR, Tebbutt N, Hill M, Ross PJ, Massey A, Oates J. Neoadjuvant Capecitabine and Oxaliplatin Followed by Synchronous Chemoradiation and Total Mesorectal Excision in Magnetic Resonance Imaging-Defined Poor-Risk Rectal Cancer. J Clin Oncol 2006, 24:668-674. 10.1200/JCO.2005.04.4875, 16446339.
8. Ryan DP, Niedzwiecki D, Hollis D, Mediema BE, Wadler S, Tepper JE, Goldberg RM, Mayer RJ. Phase I/II Study of Preoperative Oxaliplatin, Fluorouracil, and External-Beam Radiation Therapy in Patients With Locally Advanced Rectal Cancer: Cancer and Leukemia Group B 89901. J Clin Oncol 2006, 24:2557-2562. 10.1200/JCO.2006.05.6754, 16636336.
9. Machiels JP, Duck L, Honhon B, Coster B, Coche JC, Scalliet P, Humblet Y, Aydin S, Kerger J, Remouchamps V, Canon JL, Van Maele P, Gilbeau L, Laurent S, Kirkove C, Octave-Prignot M, Baurain JF, Kartheuser A, Sempoux C. Phase II study of preoperative oxaliplatin, capecitabine and external beam radiotherapy in patients with rectal cancer: the RadiOxCape study. Ann Oncol 2005, 16:1898-1905. 10.1093/annonc/mdi406, 16219623.
10. Rodel C, Grabenbauer GG, Papadopoulos T, Hohenberger W, Schmoll H-J, Sauer R. Phase I/II Trial of Capecitabine, Oxaliplatin, and Radiation for Rectal Cancer. J Clin Oncol 2003, 21:3098-3104. 10.1200/JCO.2003.02.505, 12915600.
11. Gunnlaugsson A, Anderson H, Fernebro E, Kjellén E, Byström P, Berglund A, Ekelund M, Påhlman L, Holm T, Glimelius B, Johnsson A. Multicentre phase II trial of capecitabine and oxaliplatin in combination with radiotherapy for unresectable colorectal cancer: The CORGI-L study. Eur J Cancer 2009, 45:807-813. 10.1016/j.ejca.2008.11.017, 19110416.
12. Kjellstrom J, Kjellen E, Johnsson A. In vitro radiosensitization by oxaliplatin and 5-fluorouracil in a human colon cancer cell line. Acta Oncol 2005, 44:687-693. 10.1080/02841860500247552, 16227158.
13. Folkvord S, Flatmark K, Seierstad T, Roe K, Rasmussen H, Ree AH. Inhibitory effects of oxaliplatin in experimental radiation treatment of colorectal carcinoma: does oxaliplatin improve 5-fluorouracil-dependent radiosensitivity?. Radiother Oncol 2008, 86:428-434. 10.1016/j.radonc.2007.10.012, 18006097.
14. Cividalli A, Ceciarelli F, Livdi E, Altavista P, Cruciani G, Marchetti P, Danesi DT. Radiosensitization by oxaliplatin in a mouse adenocarcinoma: influence of treatment schedule. Int J Radiat Oncol Biol Phys 2002, 52:1092-1098.
15. Withers H, Elkind M. Microcolony survival assay for cells of mouse intestinal mucosa exposed to radiation. Int J Radiat Biol 1970, 17:261-267.
16. Cai W, Roberts S, Bowley E, Hendry J, Potten C. Differential survival of murine small and large intestinal crypts following ionizing radiation. Int J Radiat Biol 1997, 71:145-155. 10.1080/095530097144265, 9120350.
17. Potten CS, Hendry JH, . Eds Cell Clones: Manual of Mammalian Cell Techniques. 1985, Churchill-Living- stone, Edinburgh, 1.
18. Hanson W, Fry R, Sallese A, Frischer H, Ahmad T, Ainsworth E. Comparison of intestine and bone marrow radiosensitivity of the BALB/c and the C57BL/6 mouse strains and their B6CF1 offspring. Radiat Res 1987, 110:340-352. 10.2307/3577002, 3588842.
19. Saif M, von Borstel R. 5-Fluorouracil dose escalation enabled with PN401 (triacetyluridine): toxicity reduction and increased antitumor activity in mice. Cancer Chemother Pharmacol 2006, 58:136-142. 10.1007/s00280-005-0129-x, 16187114.
20. Moore JV. Clonogenic response of cells of murine intestinal crypts to 12 cytotoxic drugs. Cancer Chemother Pharmacol 1985, 15:11-15.
21. de Gramont A, Bosset JF, Milan C, Rougier P, Bouche O, Etienne PL, Morvan F, Louvet C, Guillot T, Francois E, Bedenne L. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. J Clin Oncol 1997, 15:808-815.
22. Rothenberg ML, Oza AM, Bigelow RH, Berlin JD, Marshall JL, Ramanathan RK, Hart LL, Gupta S, Garay CA, Burger BG, Le Bail N, Haller DG. Superiority of Oxaliplatin and Fluorouracil-Leucovorin Compared With Either Therapy Alone in Patients With Progressive Colorectal Cancer After Irinotecan and Fluorouracil-Leucovorin: Interim Results of a Phase III Trial. J Clin Oncol 2003, 21:2059-2069. 10.1200/JCO.2003.11.126, 12775730.
23. Gunnlaugsson A, Kjellén E, Nilsson P, Bendahl P-O, Willner J, Johnsson A. Dose-volume relationships between enteritis and irradiated bowel volumes during 5-fluorouracil and oxaliplatin based chemoradiation in locally advanced rectal cancer. Acta Oncol 2007, 46:937-944. 10.1080/02841860701317873, 17851844.
24. Baglan KL, Frazier RC, Yan D, Huang RR, Martinez AA, Robertson JM. The dose-volume realationship of acute small bowel toxicity from concurrent 5-FU-based chemotherapy and radiation therapy for rectal cancer. Int J Radiat Oncol Biol Phys 2002, 52:176-183.
25. Grann A, Feng C, Wong D, Saltz L, Paty PP, Guillem JG, Cohen AM, Minsky BD. Preoperative combined modality therapy for clinically resectable uT3 rectal adenocarcinoma. Int J Radiat Oncol Biol Phys 2001, 49:987-995. 10.1016/S0360-3016(00)01529-7, 11240239.
26. Sauer R, Becker H, Hohenberger W, Rodel C, Wittekind C, Fietkau R, Martus P, Tschmelitsch J, Hager E, Hess CF, Karstens JH, Liersch T, Schmidberger H, Raab R, . German Rectal Cancer Study Group Preoperative versus Postoperative Chemoradiation for Rectal Cancer. N Engl J Med 2004, 351:1731-1740. 10.1056/NEJMoa040694, 15496622.